Biotech Executives Address Funding and Regulatory Challenges
The biotech sector is showing signs of recovery with increased IPO activity and higher M&A deal values. However, ongoing challenges such as US tariffs, geopolitical tensions, patent cliffs, and FDA instability continue to impact the industry.
Topics: FDA changes funding shifts IPOs M&A activity